menu

Multidisciplinary Perspectives in Advanced HCC: A Focus on Immune Checkpoint Inhibitors

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Multidisciplinary Perspectives in Advanced HCC:  A Focus on Immune Checkpoint Inhibitors

close
0.75 credits
45 minutes
Multidisciplinary Perspectives in Advanced HCC:  A Focus on Immune Checkpoint Inhibitors
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage HCC, with immunotherapy treatment strategies now FDA approved in both the first- and second-line settings. Several combinations of immune checkpoint inhibitors and immune checkpoint inhibitors with other targeted agents continue to be investigated in clinical trials. Results of many combination clinical trials have the potential to substantially alter the standard of care for patients with advanced HCC.

    Additionally, immune checkpoint inhibitors come with a unique set of side effects or immune-related adverse events (irAEs) due to the increased activity of the immune system. These irAEs can involve multiple organs and although they are often mild, they can be severe, irreversible, or even life-threatening. It can be challenging for clinicians to understand how to best incorporate immune checkpoint inhibitors into current treatment strategies, including irAE management.

    Liver cirrhosis and hepatic dysfunction often complicate treatment, which underscores the importance of coordinated care. Communication and collaboration through a multidisciplinary approach is vital to the treatment and management of HCC, underlying liver disease, and adverse events.

    This web-based, on-demand, multimedia expert panel discussion will feature thought leader perspectives on the latest emerging evidence, evaluation of the most recent clinical data, and provide timely evidence-based updates and expert insights on the treatment and multidisciplinary management of advanced hepatocellular carcinoma.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Assess the efficacy and safety of immune checkpoint inhibitors for the treatment of advanced HCC
    • Develop evidence-based treatment strategies with immune checkpoint inhibitors for patients with advanced HCC based on guideline recommendations
    • Integrate emerging immune checkpoint inhibitor treatment strategies being investigated in clinical trials into treatment strategies for the treatment of advanced HCC
    • Develop approaches to identify and manage immune-related adverse events that can occur with immune checkpoint inhibitors to improve patient outcomes
    • Implement a multidisciplinary team approach to optimize care coordination and the management of patients with HCC and cirrhosis
  • Target Audience

    This activity is intended for hepatologists, medical oncologists, radiologists, surgical oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals who manage hepatocellular carcinoma.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.  Richard Finn, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Bayer HealthCare, Inc; Bristol-Myers Squibb Co; Eisai Inc; CStone Pharmaceuticals; Eli Lilly and Co; Pfizer, Inc; Merck & Co, Inc; Exelixis, Inc; Roche; and Genentech, Inc. Amit Singal, MD, MS, reported a financial interest/relationship or affiliation in the form of Consultant: Genentech, Inc; Bayer HealthCare, Inc; Eisai Inc; Bristol-Myers Squibb Co; Exelixis, Inc; AstraZeneca Pharmaceuticals LP; Wako Diagnostics; Roche; Glycotest; Exact Sciences; and GRAIL. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck & Co.

    The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC;  Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck & Co.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/16/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.75 contact hour of continuing pharmacy education credit JA4008106-0000-20-056-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.75 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider

    Provided by 

  • Commercial Support

    Supported by an educational grant from Genentech, a member of the Roche Group.

  • Terms of Use

    Disclosure of Unlabeled Use         
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer   
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:       
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage HCC, with immunotherapy treatment strategies now FDA approved in both the first- and second-line settings. Several combinations of immune checkpoint inhibitors and immune checkpoint inhibitors with other targeted agents continue to be investigated in clinical trials. Results of many combination clinical trials have the potential to substantially alter the standard of care for patients with advanced HCC.

    Additionally, immune checkpoint inhibitors come with a unique set of side effects or immune-related adverse events (irAEs) due to the increased activity of the immune system. These irAEs can involve multiple organs and although they are often mild, they can be severe, irreversible, or even life-threatening. It can be challenging for clinicians to understand how to best incorporate immune checkpoint inhibitors into current treatment strategies, including irAE management.

    Liver cirrhosis and hepatic dysfunction often complicate treatment, which underscores the importance of coordinated care. Communication and collaboration through a multidisciplinary approach is vital to the treatment and management of HCC, underlying liver disease, and adverse events.

    This web-based, on-demand, multimedia expert panel discussion will feature thought leader perspectives on the latest emerging evidence, evaluation of the most recent clinical data, and provide timely evidence-based updates and expert insights on the treatment and multidisciplinary management of advanced hepatocellular carcinoma.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Assess the efficacy and safety of immune checkpoint inhibitors for the treatment of advanced HCC
    • Develop evidence-based treatment strategies with immune checkpoint inhibitors for patients with advanced HCC based on guideline recommendations
    • Integrate emerging immune checkpoint inhibitor treatment strategies being investigated in clinical trials into treatment strategies for the treatment of advanced HCC
    • Develop approaches to identify and manage immune-related adverse events that can occur with immune checkpoint inhibitors to improve patient outcomes
    • Implement a multidisciplinary team approach to optimize care coordination and the management of patients with HCC and cirrhosis
  • Target Audience

    This activity is intended for hepatologists, medical oncologists, radiologists, surgical oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals who manage hepatocellular carcinoma.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.  Richard Finn, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Bayer HealthCare, Inc; Bristol-Myers Squibb Co; Eisai Inc; CStone Pharmaceuticals; Eli Lilly and Co; Pfizer, Inc; Merck & Co, Inc; Exelixis, Inc; Roche; and Genentech, Inc. Amit Singal, MD, MS, reported a financial interest/relationship or affiliation in the form of Consultant: Genentech, Inc; Bayer HealthCare, Inc; Eisai Inc; Bristol-Myers Squibb Co; Exelixis, Inc; AstraZeneca Pharmaceuticals LP; Wako Diagnostics; Roche; Glycotest; Exact Sciences; and GRAIL. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck & Co.

    The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC;  Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck & Co.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/16/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.75 contact hour of continuing pharmacy education credit JA4008106-0000-20-056-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.75 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider

    Provided by 

  • Commercial Support

    Supported by an educational grant from Genentech, a member of the Roche Group.

  • Terms of Use

    Disclosure of Unlabeled Use         
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer   
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:       
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/22/21